

SUDARSHAN PHARMA INDUSTRIES LTD

Head Office: 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail: compliance@sudarshanpharma.com, Website: www.sudarshanpharma.com

Board Line: +91-22-42221111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2024-2025/23

Date: 31/07/2024

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INEO0TV01015

Sub: Business Updates

Ref: Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements)

Regulations, 2015

This is with regards to information and details required to be submitted under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 ("Circular") and in furtherance to letters dated SPIL/CS/SE/2024-2025/01 and SPIL/CS/SE/2024-2025/03 dated 2nd January, 2024 and 9th January, 2024 respectively submitted to BSE Limited, the Company vide this letter submits that the Company has won an award in its favour announced by the Dubai Court in Lawsuit no. 1679/2024 — Commercial against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates.

According to the award announced, (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of United Arab Emirates Dirham 40,30,934.00 (equivalent to approx. Rs.9,18,82,890/- i.e. Rupees Ninety Crores Eighteen Lakhs Eighty Two Thousand Eight Hundred And Ninety only) along with interest at 5% annually on the adjudged amount until the full payment is made.

Kindly take it on your records.

For, Sudarshan Pharma Industries Limited

Sachin V Mehta Joint Managing Director & Chief Financial Officer